Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, Read E J, Carter C, Bahceci E, Young N S, Barrett A J
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Blood. 1999 Nov 1;94(9):3234-41.
Nonmyeloablative allogeneic stem cell transplantation has recently been explored as a safer alternative to conventional high-dose transplant regimens. Although a high incidence of mixed chimerism after nonmyeloablative procedures has been reported, the exact kinetics of engrafting donor cells in specific cellular lineages has yet to be defined. We investigated lineage-specific chimerism in 15 patients receiving an allogeneic peripheral blood stem cell (PBSC) transplant from an HLA-identical (n = 14) or a 5/6 antigen-matched sibling donor after a preparative regimen of cyclophosphamide and fludarabine. Donor chimerism was assessed weekly in T lymphocytes and myeloid cells by polymerase chain reaction (PCR) of minisatellite regions. Eight patients survived between 121 to 409 days after transplant. Ten of 14 patients surviving more than 30 days (71.4%) had delayed disease regression consistent with a graft-versus-malignancy (GVM) effect. One patient rejected the transplant with subsequent recovery of autologous hematopoiesis. Hematological recovery was rapid (median, 11 days to >/=500 neutrophils/microL) and was initially predominantly recipient in origin. Donor myeloid chimerism gradually supplanted recipient hematopoiesis and became fully donor in all survivors by 200 days after transplantation. In contrast, T-cell engraftment was more rapid, with full chimerism in 7 patients by day 30 and in 6 further patients by day 200 after cyclosporine withdrawal and donor lymphocyte infusion. Full donor T-cell engraftment preceded donor myeloid engraftment, acute graft-versus-host disease, and disease regression, consistent with a requirement for 100% donor T-cell chimerism for full expression of the alloresponse. These results emphasize the importance of lineage-specific chimerism analysis to successfully manipulate engraftment after nonmyeloablative allogeneic PBSC transplantation.
非清髓性异基因干细胞移植最近已被探索作为传统高剂量移植方案的一种更安全的替代方法。尽管已有报道称非清髓性操作后混合嵌合体的发生率很高,但供体细胞在特定细胞谱系中植入的确切动力学仍有待确定。我们研究了15例接受异基因外周血干细胞(PBSC)移植患者的谱系特异性嵌合体情况,这些患者在接受环磷酰胺和氟达拉滨预处理方案后,接受了来自 HLA 相同(n = 14)或 5/6 抗原匹配的同胞供体的移植。通过对小卫星区域进行聚合酶链反应(PCR),每周评估T淋巴细胞和髓系细胞中的供体嵌合体情况。8例患者在移植后121至409天存活。14例存活超过30天的患者中有10例(71.4%)出现疾病延迟消退,符合移植物抗恶性肿瘤(GVM)效应。1例患者移植排斥,随后自体造血恢复。血液学恢复迅速(中位时间为11天至≥500个中性粒细胞/微升),最初主要起源于受者。供体髓系嵌合体逐渐取代受者造血,在移植后200天时所有存活者均完全为供体来源。相比之下,T细胞植入更快,7例患者在第30天时达到完全嵌合体,另外6例患者在停用环孢素和输注供体淋巴细胞后第200天时达到完全嵌合体。完全供体T细胞植入先于供体髓系植入、急性移植物抗宿主病和疾病消退,这与完全表达同种异体反应需要100%供体T细胞嵌合体一致。这些结果强调了谱系特异性嵌合体分析对于成功操控非清髓性异基因PBSC移植后植入的重要性。